Recent data further support this interplay, highlighting the potential of both SGLT2 inhibitors and GLP-1 receptor agonists to mitigate cardiovascular risk and reduce OSA severity through pleiotropic, multi-organ effects [23]. This evidence concerns the gene GLP1R and obstructive sleep apnea syndrome.